1 Article title: Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies

- 2 novel clusters and divergent ex-vivo drug responses
- 3
- 4 Jeppe F Severens^{1,2,3}, E Onur Karakaslar^{1,2,3}, Bert A van der Reijden⁴, Elena Sánchez-López^{3,5}, Redmar
- 5 R van den Berg⁶, Constantijn JM Halkes⁷, Peter van Balen⁷, Hendrik Veelken^{3,7}, Marcel JT Reinders^{1,2,3},
- 6 Marieke Griffioen⁷, Erik B van den Akker^{1,2,3}
- 7
- 8 ¹Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- 9 ²Pattern Recognition & Bioinformatics, Delft University of Technology, Delft, The Netherlands
- 10 ³Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, The Netherlands
- ¹¹ ⁴Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center,
- 12 Nijmegen, The Netherlands
- 13 ⁵Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
- ¹⁴ ⁶Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
- 15 ⁷Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
- 16

17 Corresponding author:

- 18 Erik B. van den Akker, PhD; Department of Biomedical Data Sciences, Leiden University Medical Center,
- 19 Leiden, The Netherlands; Einthovenweg 20, 2333 ZC, Leiden, The Netherlands; Tel: +31 (0)71 526 85
- 20 57; Fax: +31 (0)71 526 82 80; E-mail: <u>e.b.van_den_akker@lumc.nl</u>
- 21

22 Disclosure of interest

- 23 The authors declare no competing financial interests.
- 24
- 25

26 Abstract

27 Subtyping of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic abnormalities, but 28 recent literature indicates that transcriptomic phenotyping holds immense potential to further refine AML 29 classification. Here we integrated five AML transcriptomic datasets with corresponding genetic information to 30 provide an overview (n=1224) of the transcriptomic AML landscape. Consensus clustering identified 17 robust 31 patient clusters which improved identification of CEBPA-mutated patients with favourable outcomes, and 32 uncovered transcriptomic subtypes for KMT2A rearrangements (2), NPM1 mutations (5), and AML with 33 myelodysplasia-related changes (AML-MRC) (5). Transcriptomic subtypes of KMT2A, NPM1 and AML-MRC 34 showed distinct mutational profiles, cell type differentiation arrests and immune properties, suggesting 35 differences in underlying disease biology. Moreover, our transcriptomic clusters show differences in ex-vivo 36 drug responses, even when corrected for differentiation arrest and superiorly capture differences in drug 37 response compared to genetic classification. In conclusion, our findings underscore the importance of 38 transcriptomics in AML subtyping and offer a basis for future research and personalised treatment strategies. 39 Our transcriptomic compendium is publicly available and we supply an R package to project clusters to new 40 transcriptomic studies.

41 Introduction

In acute myeloid leukaemia (AML), recurrent genetic abnormalities (RGA) have been identified through systematic genomic studies.^{1–5} Based on these RGAs, the World Health Organization (WHO 2022) and International Consensus Classification (ICC 2022) define several AML subtypes, as well as a heterogeneous subtype of AML with myelodysplasia-related changes (AML-MRC).^{6,7} RGAs are essential for risk-stratification and are increasingly targeted with drugs.^{8,9}

AML subclassification is genetics-based, but transcriptomics holds immense potential to refine AML classification further.^{1–3,10–12} Transcriptomic studies have led to the discovery of *CEBPA*-mutated AML^{13,14}, and *NPM1*-mutated AML subtypes with different cell differentiation arrests and ex-vivo drug responses.^{15,16} Similar stratification would be beneficial for AML-MRC, given its heterogeneity.^{17,18} Still, a comprehensive examination of AML subtypes defined by gene expression has yet to be performed. Furthermore, the differentiation arrest state is known to modify drug response in AML¹⁹, and failing to account for this effect when comparing drug responses could skew conclusions.

Therefore, we integrated five mRNAseq datasets with corresponding genetic aberration data and annotated cases according to WHO and ICC 2022 standards. We outline AML's transcriptomic landscape and define transcriptional subtypes with distinct gene expressions, genetic aberrations, and cell type arrests. We relate the clusters to ex-vivo drug responses independently of differentiation arrest and show how they superiorly capture differences in response compared to genetic classification. We provide all harmonised data and a transcriptional cluster predictor for future research. Our study underscores the importance of incorporating transcriptomic data in AML classification.

61

62

63 Methods

64 **Transcriptomic data**

We acquired transcriptomics data of primary AML patients from blood or bone marrow from BEAT^{3,20} (n = 425), TARGET² (n = 145), TCGA¹ (n = 150), and Leucegene^{11,21–23} (n = 399), and our inhouse LUMC²⁴ dataset (n = 95). Data statements and methods for transcriptome sequencing are available in the referenced studies.

We acquired quantified gene expression for BEAT, TARGET and TCGA from https://portal.gdc.cancer.gov/ (release 36) and implemented the same pipeline for Leucegene and LUMC to harmonise quantification. In short, FASTQ files were aligned and quantified with STAR²⁵ to the GRCh38 reference genome²⁶, using Gencode v36²⁷ as the gene annotation index which included 60600 genes.

Gene expression count data were corrected with Combat-Seq²⁸ for the variables "cohort", "sex", and "tissue". We split Leucegene for the batch correction into Leucegene_stranded and Leucegene_unstranded, since different sequencing libraries were used. We removed 8057 genes that were not detected in all cohorts, leaving 52603 genes. Finally, we removed genes detected in less than 200 samples or with less than 300 counts leaving 41862 genes for our final dataset. We normalised the corrected count data using the geometric mean and variance stabilising transformation (VST)²⁹ and quantified the remaining cohort-specific variation using kBET.³⁰

81

82 Genetic and patient data

We acquired genetic data for the samples from the referenced studies in the form of mutation and
fusion calling, and cytogenetics data and clinical data on sex, age, blast percentage, and survival.
Blacklisted fusions as reported by Arriba³¹ were removed from the fusion calling data.

We harmonised the data by standardising the annotation of gene names, fusion genes, and karyotyping. Using genetic data, we subclassified samples according to the WHO 2022⁶ and ICC 2022⁷. Samples for which we found no RGA and all genetic data available were annotated as "No RGA found". We classified samples with missing data and "No RGA found" as "Inconclusive".

90

91 Clustering

We employed consensus clustering^{32,33} on the batch-adjusted gene expression. First, we created a weighted nearest neighbour graph³⁴ using the 2000 most variable genes (MVGs). MVGs were selected via the median absolute deviation from samples with a blast percentage over 70% to minimise tumour microenvironment effects. Using the Leiden algorithm³⁵ – with seed and resolution varied per iteration – we generated 300 cluster assignments from the graph for each n_clusters ranging from 10 to 20, totaling 3300 assignments.

From these 3300 assignments we created a consensus matrix with values ranging between 0 and 1 based on pairwise co-clustering. We then converted this matrix into a distance matrix (1 consensus matrix) and conducted Ward.D2 hierarchical clustering. The final cluster count was determined based on the individual separation of WHO classes and clusters displaying differential traits.

102

103 Cluster stability

To evaluate per sample clustering stability, we devised a stability score. We constructed a consensus matrix for each n_clusters (300 assignments) and subtracted each co-clustering value from 1 if it was below 0.5. Then, we took the mean of all values per sample as the stability score, which ranged from 0.5 to 1, with higher scores indicating less clustering ambiguity. To investigate correlation between cluster stability and blast percentage we performed a Spearman correlation test. Additionally, we generated tSNEs using 100 to 2500 MVGs to visually assess cluster stability.

110

111 Cluster prediction

112 To predict cluster assignments we trained a one-vs-rest SVM per cluster. As input we used the 113 uncorrected gene expression of the 2000 MVGs used for clustering. To select hyperparameters and 114 evaluate performance we utilised 5x5 nested cross-fold validation.

To improve predictions we included a reject option using a minimum distance to the decision boundary. We determined this distance by looping over possible minimum values for the predictions of the inner fold. We selected the minimum value with the highest Kappa for the accepted inner fold samples and an accuracy < 0.5 for the rejected inner folds samples.

119 The final model was trained on the whole dataset, using 5-fold cross-validation to select120 hyperparameters and the minimum decision boundary distance.

121 Differential gene expression analysis

Differential gene expression analysis between the clusters was performed using DESeq2²⁹ using the corrected gene counts. We performed one-versus-rest analyses to identify differentially expressed genes in one cluster compared to all others. We annotated genes as transcription factors or coding for cell surface proteins using public databases.^{36,37}

126

127 Aberration enrichment analysis

To test if aberrations occurred more in a cluster than in others we first removed aberrations found in only one cohort or which occurred in less than 1% of the samples. We also included high *MECOM* expression in the analysis (VST expression > 6, based on the tail of a *MECOM* expression density plot). We tested for enrichment per aberration by performing an one-sided Fisher exact test for one cluster versus all others and adjusted p-values using the Benjamini-Hochberg (BH) procedure. We considered aberrations with a false discovery ratio (FDR) < 0.05 enriched.

134

135 Survival analysis

We performed survival analysis using right censored overall survival data by generating Kaplan Meier (KM) curves on BEAT and TCGA survival data, comparing different groups of patients with the log rank test. We also performed Cox-regression using BEAT, TARGET and TCGA survival data for different patient groups and included cohort, sex and age as co-variables to analyse hazard ratios.

140

141 Expression based score

We created cell type score to assess the differentiation arrest of AML samples, using the mean expression of 30 marker genes for six haematological cells.³⁸ Additionally, we created immune phenotype scores for cytolytic infiltration and HLA I and HLA II antigen presenting cells using the mean expression of marker genes.³⁹

146

147 **Drug response analysis**

To analyse drug response differences, we used ex-vivo drug response data of 331 BEAT³ samples, quantified as area under the curve (AUC). We excluded drugs with less than 200 samples or missing data for any cluster, leaving 103 of the 123 drugs. We used a Kruskal-Wallis test for each drug with the AUC as response and clusters as groups to compare the average drug response per cluster.

152 Drugs with a significant difference (FDR<.05) were analysed with one-sided Wilcoxon tests to identify

153 clusters with low AUCs. Additionally, we performed a Kruskal-Wallis test for each drug with the ICC 2022

154 diagnosis as groups, to compare with clusters as groups.

Multivariate linear models (LM) were evaluated per drug to test if clusters were sensitive to a drug when adjusted for cell type, with AUC as response and cluster membership (one-versus-rest) and the six cell type scores as explaining variables. Similarly, we fitted LMs but with cluster membership and ICC 2022 diagnoses as variables. We considered clusters sensitive to a drug if the cluster membership's FDR was below 0.05 and the LM coefficient was negative. All p-values were corrected using BH.

160

161 Data Sharing Statement

162 The datasets generated and/or analysed during the current study are available from 163 www.github.com/jeppeseverens/AMLmap.

164

165 **Code availability**

All code used to generate results is available on reasonable request. The predictor is available from
 www.github.com/jeppeseverens/AMLmapR as an R package.

168

169 Results

170 Multi-cohort AML gene expression compendium

We collected 1224 RNAseq samples from adult (BEAT, TARGET, TCGA, Leucegene, LUMC) and paediatric (TARGET) cohorts with corresponding genetic and clinical data (**Figure 1A**). We quantified gene expression with the same pipeline and corrected counts for cohort, sex and source tissue (**Supplemental Figure 1**). Sample classification by their genetic data according to the WHO (**Figure 1C**) and ICC was successful for 97% of the samples. In line with previous reports, frequencies of the AML subtypes were similar for the adult cohorts but different between paediatric and adult cohorts (**Supplemental Table 1**), confirming that our dataset is representative of the AML landscape.^{40,5}

178 Transcriptomics define 17 AML clusters

Next, we assigned AML cases to 17 transcriptional clusters using consensus clustering (Figure
 Supplemental Figures 2 & 3). We named the clusters based on genetic diagnoses (Figure 1B,
 Supplemental Figure 4 & 5). As expected, the distribution over the clusters was different for paediatric

and adult cohorts, exemplified by the large percentage of paediatric samples in the KMT2A^T clusters
(26%), and adult samples in the NPM1^T (93%) and AML-MRC^T (94%) clusters (Supplemental Table 1,
Supplemental Figure 6). However, samples of identical AML genetic subtypes from adult and paediatric
cohorts clustered together, indicating that the 17 clusters capture differences in AML biology.

We examined clustering robustness using the stability score (**Supplemental Figure 7**). Median clustering stability was high (0.97-1.00), with AML-MRC(3)^T showing the lowest stability. A correlation test revealed a significant but weak correlation (rho = 0.18, p-value<.001) between blast percentage and clustering robustness, but blast percentage varied greatly in clusters. tSNEs generated using different MVGs (**Supplemental Figure 8**) were stable from 500 to 2500 features. These results show that clustering was robust and only weakly influenced by blast percentage.

We developed a transcriptional cluster predictor using uncorrected counts as input (accuracy = 0.90), demonstrating the persistence of expression patterns. The quality of the predictor was further improved (accuracy = 0.95) by including a reject option (10% rejected) (**Supplemental Figure 9**).

195 Next, we tested for enrichment of mutations, fusions and cytogenetic aberrations (n=102) (Figure 196 1E, p-values and frequencies in **Supplemental Table 2**). Four transcriptomic clusters corresponded to 197 singular genetic AML subtypes: RUNX1::RUNX1T1^T (RUNX1::RUNX1T1: 94%, FDR<.001), 198 CBFB::MYH11^T (*CBFB::MYH11*: 95%, FDR<.001), PML::RARA^T (*PML::RARA*: 100%, FDR<.001), and 199 NUP98^T (NUP98::NSD1: 45%, FDR<.001). Risk-stratification for survival based on transcriptional 200 subtypes performed similarly to genetics (Supplemental Figure 10 & 11). We identified no enrichment 201 for BCR::ABL1 and DEK::NUP214, possibly due to their limited occurrence. For KMT2A rearrangements, 202 CEBPA mutations, NPM1 mutations, and AML-MRC, we found evidence that transcriptomics can refine 203 subtyping, as described below.

204

205 Transcriptome analysis identifies two *KMT2A*-related clusters

The WHO classification defines a single *KMT2A*-rearranged subtype (*KMT2A*-r), while the ICC recognises *KMT2A::MLLT3* and other *KMT2A* fusions as distinct.^{6,7} We identified two *KMT2A* fusion clusters. KMT2A(1)^T was significantly enriched for *KMT2A::MLLT3* (31%, FDR<.001), *KMT2A::MLLT10* (19%, FDR<.001) and any *KMT2A* fusion (67%, FDR<.001), while KMT2A(2)^T was enriched for *KMT2A::MLLT4* (67%, FDR<.001) and high *MECOM* expression (80%, FDR<.001) (**Figures 2A & B**).

211 Interestingly, we found cases with *NPM1* mutations and trisomy 8/8q localised in KMT2A(1)^T, indicating

that these lead to *KMT2A* fusion-like gene expression.

213 The genes LAMP5, and ADCY9 showed high expression in KMT2A(1)^T and low expression in 214 KMT2A(2)^T (Figure 2B), and all have been shown to contribute to AML pathogenesis^{41,42}. Additionally, 215 the transcription factor (TF) ETV2 was highly expressed in KMT2A(1)^T, while the TF ERG displayed high expression in KMT2A(2)^T. The cell type scores revealed KMT2A(1)^T to have a significantly higher 216 217 promonocyte-like score (FDR<.001), while KMT2A(2)^T was more hematopoietic stem cell (HSC)-like 218 (FDR<.001) (Figure 2B, Supplemental Figure 12). FAB annotations showed similar results for 219 KMT2A(1)^T, which had a high M5 (monocytic leukaemia) fraction (90%), while KMT2A(2)^T was more 220 mixed (Figure 2C). Overall, we found that gene expression-based separation of KMT2A-r did not align 221 with the ICC 2022 classification.

222

223 The CEBPA^T cluster indicates a favourable prognosis

224 As acknowledged in the ELN2022, patients with a CEBPA bZIP inframe mutation have a 225 favourable prognosis.^{8,43} We identified a transcriptional CEBPA^T cluster significantly enriched for mutated 226 CEBPA cases (72%, FDR<.001), with 42% of the samples having a CEBPA bZIP indel, either as single 227 mutation or combined with an N-terminal frameshift mutation (Figure 3A & B). The remaining samples 228 contained other mutations in the bZIP area or N-terminal region or had no detectable CEBPA mutation. 229 Of note, a single CEBPA bZIP indel case resided outside the CEBPA^T cluster. This patient had an IDH-230 R132 mutation with a VAF=0.47, while the CEBPA bZIP in-frame mutation had a VAF=0.21. This finding 231 suggests that the IDH-R132 mutation dominates the expression pattern, placing this case in cluster AML-232 MRC(1)^T. Conversely, all CEBPA^T cluster patients showed similar favourable outcomes (log-rank test: p-233 value=.80), irrespective of whether the CEBPA bZIP inframe mutation was detected (Figure 3C). The 234 CEBPA^T cluster thus marks patients with a favourable outcome regardless of CEBPA mutation detection, 235 which the CEBPA^T expression profile can detect.

236 Gene expression profiling identifies five transcriptional *NPM1*-related clusters

The 2022 WHO and ICC classifications include one subtype of *NPM1*-mutated AML.^{6,7} However, we identified five clusters enriched for mutated *NPM1* (**Figure 4**). We observed elevated expression of *HOXA3*, *HOXB5*, and *MEIS1* (**Figure 4A**), which has been earlier associated with *NPM1* mutations.⁴⁴

Interestingly, *NPM1* mutation-lacking samples generally also exhibited high expression of these genes, suggesting that there are alternative mishaps that disrupt these genes leading to *NPM1* mutated-like AML.

243 NPM1(1)^T exhibited the highest percentage (95%, FDR<.001) of NPM1 mutated samples and 244 was significantly enriched for IDH1-R132 (25%, FDR<.001), IDH2-R140 (37%, FDR<.001), and TET2 (33%, FDR<.001) co-mutations (Figure 4A). NPM1(2)^T samples were enriched for *FLT3*-ITD mutations 245 246 (84%, FDR<.001), but *FLT3*-ITD was also enriched in NPM1(1)^T, NPM1(3)^T and NPM1(4)^T (42-43%, all 247 FDR<.001). Additionally, NPM1(4)^T and NPM1(5)^T had a significantly lower variant allele frequency for 248 mutated NPM1 (Figure 4B). We found two NPM1::MLF1 cases in our compendium, which both clustered 249 in NPM1(3)^T. NPM1::MLF1 has been shown to localise in the cytoplasm⁴⁵, like mutated NPM1, possibly 250 leading to a similar expression profile as NPM1-mutated cases.

Each of the *NPM1*-related clusters exhibited unique marker genes (**Figure 4A**). For instance, *FTO* expression was high in NPM1(1)^T. Additionally, *LYRM1*, *ADAM8*, and *DNAJC13* were elevated in NPM1(2)^T, NPM1(4)^T, and NPM1(5)^T, respectively. NPM1(3)^T had a less distinct expression pattern, suggesting a more heterogeneous cluster. Also, we observed differential expression of TFs (*RUNX1*, *PRDM16*, *SPI1*)^{46,47} – even in samples lacking the *NPM1* mutation – and TF expression aligned with cell differentiation stages.

NPM1(1)^T and NPM1(2)^T displayed a HSC-like expression pattern, NPM1(3)^T was mixed, 257 258 whereas NPM1(4)^T and NPM1(5)^T were more differentiated (Figure 4A, Supplemental Figure 12). FAB annotations showed additional differences, with NPM1(5)^T containing fewer M4 (myelomonocytic 259 260 leukaemia) but more M5 (monocytic leukaemia) cases than NPM1(4)^T (Figure 4C & D). Using scores for 261 HLA I and HLA II antigen-presenting cells³⁹ we found NPM1(1)^T to have significantly lower HLA I 262 (FDR<.001) and HLA II (FDR<.001) scores than the other clusters (**Figure 4E & F**). NPM1(1)^T and 263 NPM1(5)^T patients were significantly older (FDR<.05), while NPM1(3)^T patients were younger (FDR<.01) 264 (Supplemental Figure 6F). Our findings emphasise the existence of distinct NPM1-related subsets, 265 highlighting the limitations of relying solely on genetic classification.

266 Gene expression profiling identifies five transcriptional AML-MRC-related clusters

267 The ICC 2022 divides AML-MRC into three groups based on TP53 mutations, myelodysplasia-268 related gene mutations, and cytogenetic abnormalities.⁷ Our study identified five gene expression-based

AML-MRC related clusters (**Figure 5**), with varying fractions of *TP53* mutations, MRC gene mutations, and cytogenetic abnormalities.

271 Despite sharing these mishaps, each cluster had unique characteristics (Figure 5A). AML-272 $MRC(1)^{T}$ was characterised by *IDH1*-R132 (49%, FDR<.001) and *IDH2*-R170 (27%, FDR<.001) 273 mutations. A DNMT3A and IDH1/2 mutated subtype has been reported⁵, but 41% of the AML-MRC(1)^T cases lacked *DNMT3A* mutations. AML-MRC(2)^T, AML-MRC(3)^T, and AML-MRC(4)^T were all enriched 274 275 (FDR<.001) for TP53 mutations, cytogenetic abnormalities and high MECOM expression, and AML-276 $MRC(3)^{T}$ also contained a large fraction of mutated MRC genes (65%, FDR<0.001). AML-MRC(5)^{T} stood 277 out with the highest fraction of mutated MRC genes cases (81%, FDR<.001) and the lowest fraction of 278 TP53 mutations (6%) and cytogenetic abnormalities (34%).

279 We found marker genes for all clusters (Figure 5A). For instance, high SRSF12 marked AML-280 MRC(1)^T, and *LINC00865* marked AML-MRC(5)^T. AML-MRC(2)^T presented high glycophorin genes and UROD expression, suggesting an association with acute erythroid leukaemia.48-50 Distinct cell 281 282 differentiation scores further highlighted differences (Figure 5A-C, Supplemental Figure 12). For 283 example, AML-MRC(1)^T showed high progenitor-like scores, with 65% M1 (minimal maturation) cases. 284 and AML-MRC(3)^T showed a more differentiated pattern, with 54% M2 (significant maturation) cases. 285 AML-MRC(2)^T was the only cluster with M6 (erythroid leukaemia) – in line with high expression of 286 erythrocyte cell markers - and M7 (megakaryocytic leukaemia) cases. Additionally, high cytolytic cell 287 infiltration has been reported for AML-MRC cases.³⁹ Using the same score (Figure 5D) we found that the 288 cytolytic infiltration was significantly (FDR<.05) lower for AML-MRC(1)^T and higher for AML-MRC(2)^T 289 compared to the other AML-MRC clusters. Our results demonstrate that different AML-MRC 290 transcriptomic clusters can be identified, showing genetic enrichments that do not necessarily align with 291 the ICC 2022 classification.

292 AML clusters exhibit cell type-independent differences in ex-vivo drug responses

Finally, we assessed the drug sensitivity of the transcriptional AML subtypes. Using ex-vivo drug response data, we discovered 101 drug-cluster combinations with significantly lower resistance (FDR<.05), of which 21 combinations remained statistically significant (FDR<.05) when adjusting for cell differentiation status (**Figure 6**, **Supplemental Figure 13**, **Supplemental Table 3**).

The ex-vivo drug responses between *NPM1*-related clusters were often divergent, exemplified by venetoclax and selumetinib (**Figure 6A,B**). NPM1(1)^T, NPM1(2)^T and NPM1(3)^T mostly responded positively to tyrosine kinase inhibitors and CDK kinase inhibitors. NPM1(4)^T and NPM1(5)^T samples were more sensitive to PI3K and MAPK kinase inhibitors. We also found drugs where only one cluster was responsive, exemplified by axitinib for NPM1(4)^T where this effect remained significant (FDR<.05) when controlled for cell type scores (**Figure 6C**).

303 Several drugs demonstrated favourable ex-vivo responses in KMT2A(1)^T compared to the other 304 clusters, exemplified by idelalisib. For KMT2A(2)^T we found no significant responsive drugs, but testing 305 was limited due to small cluster size. For the AML-MRC clusters, most drugs showed strong resistance. 306 Still, specific drugs were more effective for AML-MRC(1)^T, AML-MRC(4)^T, and AML-MRC(5)^T (**Figure 6A**, 307 **B**), suggesting potential for targeted treatments in this diverse, high-risk patient group.

Next, we examined if transcriptional clusters provide insights beyond genetic classifications. Comparing the AUCs of each drug between groups, we found 71 drugs with significantly different (FDR<.05) median AUCs between the clusters, while only 21 drugs were significantly different between ICC 2022 classes (**Figure 6D**). Additionally, 57 of the 101 cluster-drug combinations remained significant (FDR<.05) when cluster membership and ICC 2022 diagnosis were included in a LM, suggesting that the transcriptional clusters offer information beyond genetic classification.

Overall, our findings offer novel opportunities for targeted therapy in AML. We observed effective drug responses even after adjusting for differentiation status, possibly allowing gene expression-based subtypes to guide treatment strategies.

317 Discussion

This study presents an overview of transcriptomics in AML and provides a framework for transcriptional subtyping. We integrate multiple cohorts to identify 17 robust transcriptional subtypes that subclassify ~75% of our datasets' patients. We make the harmonised data and a cluster predictor publicly available, facilitating future research.

For the CEBPA^T cluster, we show that patients without a detected *CEBPA* bZIP indel mutation still have similar favourable survival. Patients without the canonical *CEBPA* mutation in the CEBPA^T cluster could be explained by undetected mutations, given the complexities of CEBPA sequencing. Also,

325 *CEBPA* hypermethylation has been described to lead to a similar expression profile.⁵¹ The use of the 326 CEBPA^T gene signature for risk stratification could be a relevant alternative to detect these favourable-327 outcome patients.

328 KMT2A(1)^T mainly featured *KMT2A* with the fusion partners *MLLT3*, *MLLT10* and *MLLT1* – all 329 TFs in the super elongation complex whose perturbation leads to disrupted hematopoietic lineage 330 commitment.⁵² In contrast, KMT2A(2)^T featured *KMT2A::MLLT4*, which is thought to cause leukaemia by 331 promoting self-association⁵³. Interestingly, *MLLT3*, *MLLT10* and *MLLT1* all fuse a specific region of 332 *KMT2A*, but *MLLT4* shows less specificity.⁵⁴ Collectively, these results suggest that two types of 333 oncogenic mechanisms involving *KMT2A* fusions exist that may be marked with unique gene expression 334 patterns.

335 We identified five NPM1-related clusters, further underpinning findings of transcriptional 336 heterogeneity among NPM1-mutated patients^{15,16,55}, but also providing additional insight into co-337 mutations and detailed subtypes. We observed several samples from NPM1-related clusters that lacked 338 the NPM1 mutation. Several rare NPM1 fusions, like NPM1::MLF1, have been described to lead to 339 cytoplasmic localisation of NPM1, comparable to the canonical NPM1 frameshift.^{45,56} These non-340 canonical mishaps could lead to a NPM1-mutated-like presentation and similarities in survival and drug 341 response should be explored. Additionally, NPM1(1)^T was mutually exclusive enriched for *IDH1/2* and 342 TET2 co-mutations. IDH1/2 mutations lead to an aberrant alpha-ketoglutarate metabolism and are functionally complementary to TET2 loss-of-function mutations ⁵⁷. While NPM1(1)^T and NPM1(5)^T show 343 344 significant enrichments for TET2, only NPM1(1)^T shows this mutual exclusivity with IDH1/2. This suggests 345 that only NPM1(1)^T is driven by aberrant alpha-ketoglutarate metabolism, which should be further studied 346 using metabolomics.

Similarly, cytogenetic abnormalities, AML-MRC mutations and high MECOM expression were found in all AML-MRC clusters, but lead to different gene expression. A possible explanation could be clonal architecture and the differentiation state of the cell acquiring the leukemic aberration, both known to influence the biology of the resultant leukaemia.^{58,59} To our knowledge, we are the first to show different gene expression-based subgroups in AML-MRC, with divergent drug responses. Accurate identification of these clusters requires gene expression analysis, showing the relevance of our work.

353 We found no additional survival differences between other clusters. However, data availability 354 limited the survival analysis, and different treatment protocols across studies could have led to

355 confoundment. Survival differences between transcriptional subtypes should thus be further explored in 356 one large cohort. However, we did find marked differences in drug responses between the clusters. 357 Ideally, new studies should test in-patient efficacy of drugs with good ex-vivo responses in transcriptional 358 subtypes. Furthermore, transcriptional subtyping could aid AML specialists in the highly complex field of 359 clinical care and lead to multidisciplinary tailored-based treatment advice.⁶⁰

360 In conclusion, the transcriptional subtypes reveal heterogeneity in AML not captured by genetic 361 classification. Integration of transcriptomics into AML research and diagnostics could improve disease 362 understanding and lead to more treatment options.

363

364 Acknowledgements

365 This project was funded by a strategic investment of the Leiden University Medical Center, embedded

366 within the Leiden Oncology Center, and executed within the Leiden Center for Computational Oncology.

367 EvdA was funded by a personal grant from the Dutch Research Council (NWO; VENI: 09150161810095).

368 The funding bodies had no role in the study design, the collection, analysis, and interpretation of data,

the writing of the manuscript, and the decision to submit the manuscript for publication.

370

Author Contributions

M.J.R., M.G., and E.B.A. conceived and designed the project; E.B.A. acquired funding; E.B.A. performed project administration; M.G., E.B.A., H.V., R.R.B., C.J.M.H., P.B. performed oversight and management of resources (data generation, collection, transfer, infrastructure, data processing); J.F.S. performed computational and statistical analyses; J.F.S., E.B.A., M.G., E.O.K., E.S.-L. performed analyses and interpretation; J.F.S. performed and structured data visualisation; M.J.R., M.G. and E.B.A. provided supervision and scientific direction; J.F.S. wrote the manuscript; and all authors critically reviewed the manuscript and figures.

379

380 Disclosure of interest

381 The authors declare no competing financial interests.

382

383 References

1. The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De

- 385 Novo Acute Myeloid Leukemia. *N. Engl. J. Med.* 2013;368(22):2059–2074.
- Farrar JE, Schuback HL, Ries RE, et al. Genomic Profiling of Pediatric Acute Myeloid Leukemia
 Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. *Cancer Res.* 2016;76(8):2197–2205.
- 389 3. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid
 390 leukaemia. *Nat. 2018 5627728*. 2018;562(7728):526–531.
- Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute
 Myeloid Leukemia. *N. Engl. J. Med.* 2016;374(23):2209–2209.
- Tazi Y, Arango-Ossa JE, Zhou Y, et al. Unified classification and risk-stratification in Acute Myeloid
 Leukemia. *Nat. Commun.* 2022;13(1):4622.
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification
 of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*.
 2022;36(7):1703–1719.
- 398 7. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid
 399 Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*.
 400 2022;140(11):1200–1228.
- 401 8. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022
 402 recommendations from an international expert panel on behalf of the ELN. *Blood*.
 403 2022;140(12):1345–1377.
- Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia
 using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master
 Trial. *Nat. Med.* 2020;26(12):1852–1858.
- 407 10. Valk PJM, Verhaak RGW, Beijen MA, et al. Prognostically Useful Gene-Expression Profiles in
 408 Acute Myeloid Leukemia. *N. Engl. J. Med.* 2004;350(16):1617–1628.
- 409 11. Lavallée V-P, Baccelli I, Krosl J, et al. The transcriptomic landscape and directed chemical
 410 interrogation of MLL-rearranged acute myeloid leukemias. *Nat. Genet.* 2015;47(9):1030–1037.
- 411 12. Mou T, Pawitan Y, Stahl M, et al. The transcriptome-wide landscape of molecular subtype-specific
 412 mRNA expression profiles in acute myeloid leukemia. *Am. J. Hematol.* 2021;96(5):580–588.
- 413 13. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, et al. Double CEBPA mutations, but not
- single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene
 expression profile that is uniquely associated with a favorable outcome. *Blood.* 2009;113(13):3088–
 2004
- 416 3091.
- 41714. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and418gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal
- 419 AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
- 420 Blood. 2011;117(8):2469–2475.
- 421 15. Mer AS, Heath EM, Madani Tonekaboni SA, et al. Biological and therapeutic implications of a
 422 unique subtype of NPM1 mutated AML. *Nat. Commun.* 2021;12(1):1054.
- 423 16. Cheng W-Y, Li J-F, Zhu Y-M, et al. Transcriptome-based molecular subtypes and differentiation
- 424 hierarchies improve the classification framework of acute myeloid leukemia. *Proc. Natl. Acad. Sci.*

425 2022;119(49):e2211429119. 426 17. de Leeuw DC, Ossenkoppele GJ, Janssen JJWM. Older Patients with Acute Myeloid Leukemia 427 Deserve Individualized Treatment. Curr. Oncol. Rep. 2022;24(11):1387-1400. 428 18. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in 429 the Netherlands: a long haul is needed to change nothing into something | Leukemia. 430 19. Zeng AGX, Bansal S, Jin L, et al. A cellular hierarchy framework for understanding heterogeneity 431 and predicting drug response in acute myeloid leukemia. Nat. Med. 2022;28(6):1212-1223. 432 20. Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in 433 acute myeloid leukemia. Cancer Cell. 2022;40(8):850-864.e9. 434 21. Macrae T, Sargeant T, Lemieux S, et al. RNA-Seg reveals spliceosome and proteasome genes as 435 most consistent transcripts in human cancer cells. PloS One. 2013;8(9):e72884. 436 22. Lavallée V-P, Lemieux S, Boucher G, et al. RNA-sequencing analysis of core binding factor AML 437 identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. Blood. 438 2016;127(20):2498-2501. 439 23. Pabst C, Bergeron A, Lavallée V-P, et al. GPR56 identifies primary human acute myeloid leukemia 440 cells with high repopulating potential in vivo. Blood. 2016;127(16):2018-2027. 441 24. Arindrarto W, Borràs DM, de Groen RAL, et al. Comprehensive diagnostics of acute myeloid 442 leukemia by whole transcriptome RNA sequencing. Leuk. 2020 351. 2020;35(1):47-61. 443 25. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma. 444 Oxf. Engl. 2013;29(1):15–21. 445 26. Genome Reference Consortium. 446 27. Frankish A, Diekhans M, Jungreis I, et al. GENCODE 2021. Nucleic Acids Res. 2021;49(D1):D916-447 D923. 448 28. Zhang Y, Parmigiani G, Johnson WE. ComBat-seg: batch effect adjustment for RNA-seg count 449 data. NAR Genomics Bioinforma. 2020;2(3):lgaa078. 450 29. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq 451 data with DESeq2. Genome Biol. 2014;15(12):550. 452 30. Büttner M, Miao Z, Wolf FA, Teichmann SA, Theis FJ. A test metric for assessing single-cell RNA-453 seq batch correction. Nat. Methods. 2019;16(1):43-49. 454 31. Uhrig S, Ellermann J, Walther T, et al. Accurate and efficient detection of gene fusions from RNA 455 sequencing data. Genome Res. 2021;31(3):448-460. 456 32. Monti S, Tamayo P, Mesirov J, Golub T. Consensus Clustering: A Resampling-Based Method for 457 Class Discovery and Visualization of Gene Expression Microarray Data. Mach. Learn. 458 2003;52(1):91-118. 459 33. Jeub LGS, Sporns O, Fortunato S. Multiresolution Consensus Clustering in Networks. Sci. Rep. 460 2018;8(1):3259. 461 34. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for 462 Dimension Reduction. 2020;

35. Traag VA, Waltman L, van Eck NJ. From Louvain to Leiden: guaranteeing well-connected
communities. *Sci. Rep.* 2019;9(1):5233.

- 465 36. Lambert SA, Jolma A, Campitelli LF, et al. The Human Transcription Factors. Cell.
- 466 2018;172(4):650–665.
- 37. Bausch-Fluck D, Hofmann A, Bock T, et al. A Mass Spectrometric-Derived Cell Surface Protein
 Atlas. *PLOS ONE*. 2015;10(4):e0121314.
- 38. van Galen P, Hovestadt V, Wadsworth II MH, et al. Single-Cell RNA-Seq Reveals AML Hierarchies
 Relevant to Disease Progression and Immunity. *Cell*. 2019;176(6):1265-1281.e24.
- 471 39. Dufva O, Pölönen P, Brück O, et al. Immunogenomic Landscape of Hematological Malignancies.
 472 *Cancer Cell*. 2020;38(3):380-399.e13.
- 473 40. Patel JP, Gönen M, Figueroa ME, et al. Prognostic Relevance of Integrated Genetic Profiling in
 474 Acute Myeloid Leukemia. *N. Engl. J. Med.* 2012;366(12):1079–1089.
- 475 41. Gracia-Maldonado G, Clark J, Mulloy JC, Kumar AR. LAMP5 a Novel Target of MLL-Fusion
 476 Proteins Is Required for the Propagation of Leukemia. *Blood.* 2016;128(22):1512.
- 477 42. Milan T, Celton M, Lagacé K, et al. Epigenetic changes in human model KMT2A leukemias
 478 highlight early events during leukemogenesis. *Haematologica*. 2022;107(1):86–99.
- 43. Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute
 myeloid leukemia. *Blood Adv.* 2022;6(1):238–247.
- 48. Brunetti L, Gundry MC, Sorcini D, et al. Mutant NPM1 maintains the leukemic state through HOX
 482 expression. *Cancer Cell*. 2018;34(3):499-512.e9.
- 483 45. Falini B, Bigerna B, Pucciarini A, et al. Aberrant subcellular expression of nucleophosmin and NPM484 MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML.
 485 Leukemia. 2006;20(2):368–371.
- 486 46. Aguilo F, Avagyan S, Labar A, et al. Prdm16 is a physiologic regulator of hematopoietic stem cells.
 487 *Blood*. 2011;117(19):5057.
- 488 47. Imperato MR, Cauchy P, Obier N, Bonifer C. The RUNX1–PU.1 axis in the control of
 489 hematopoiesis. *Int. J. Hematol.* 2015;101(4):319–329.
- 48. Hollox EJ, Louzada S. Genetic variation of glycophorins and infectious disease. *Immunogenetics*.
 2022;
- 49. Greaves MF, Sieff C, Edwards PAW. Monoclonal Antiglycophorin as a Probe for Erythroleukemias.
 493 *Blood*. 1983;61(4):645–651.
- 494 50. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human
 495 leukaemia cell line K562. *Nature*. 1979;278(5702):364–365.
- 496 51. Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM, et al. Characterization of
 497 CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
- 498 *Haematologica*. 2011;96(3):384–392.
- 499 52. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL500 based leukaemogenesis. *Nat. Rev. Cancer.* 2010;10(10):721–728.
- 501 53. Liedtke M, Ayton PM, Somervaille TCP, Smith KS, Cleary ML. Self-association mediated by the
 502 Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. *Blood*.
 503 2010:116(1):63–70.
- 504 54. Meyer C, Larghero P, Almeida Lopes B, et al. The KMT2A recombinome of acute leukemias in

505 2023. *Leukemia*. 2023;37(5):988–1005.

- 506 55. Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O. A distinct immunophenotype
- identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
 Am. J. Hematol. 2018;93(4):504–510.
- 509 56. Martelli MP, Rossi R, Venanzi A, et al. Novel NPM1 exon 5 mutations and gene fusions leading to 510 aberrant cytoplasmic nucleophosmin in AML. *Blood*. 2021;138(25):2696–2701.
- 511 57. Figueroa ME, Wahab OA, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a
- hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell.* 2010;18(6):553–567.
- 514 58. Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high-515 throughput single-cell genomics. *Nat. Commun.* 2020;11(1):5327.
- 516 59. Krivtsov AV, Figueroa ME, Sinha AU, et al. Cell of origin determines clinically relevant subtypes of 517 MLL-rearranged AML. *Leukemia*. 2013;27(4):852–860.
- 518 60. Willemsen AECAB, Krausz S, Ligtenberg MJL, et al. Molecular tumour boards and molecular
- 519 diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
- 520 Br. J. Cancer. 2019;121(1):34–36.

521 Figure legends

522 Figure 1: Transcriptomic analysis further stratifies AML.

523 A) Flowchart of the used data and methods. B) Sankey plot showing the assignment of WHO 2022 524 diagnoses over the identified clusters. C) tSNE visualisation of the gene expression of patient samples. 525 Each dot represents a patient. The samples are coloured according to the WHO 2022 subtyping of AML. 526 D) The same tSNE visualisation as in C, but samples are coloured according to the 17 clusters. E) Dot 527 plots that show enriched aberrations in the 17 clusters. The dots are coloured according to the adjusted 528 p-value. The dots are sized according to the sample fraction with the aberration in the cluster. The x-axis 529 shows the aberrations, and the y-axis shows the clusters. We only visualised enriched aberrations that 530 occurred in at least 10% of the patients in a cluster.

531

532 Figure 2: Transcriptome analysis identifies two *KMT2A*-related clusters.

A) tSNE visualisation of patient samples, coloured according to *KMT2A*-fusion or *NPM1* mutation and trisomy 8. **B)** Waterfall plot of aberrations in the KMT2A clusters, including the percentage of samples with the aberration. The plot is combined with heatmaps showing the expression of marker genes and cell type scores. The columns are samples, which are split according to transcriptional clusters. **C)** Fraction of FAB annotations per cluster. HSC = hematopoietic stem cells, Prog. = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. = monocytes, cDC = conventional dendritic cells

540

541 Figure 3: The CEBPA^T cluster indicates a favourable prognosis.

A) Waterfall plot and gene expression heatmap of all samples in the CEBPA^T cluster and samples with a *CEBPA* mutation located outside the CEBPA^T cluster. **B**) tSNE visualisation of patient samples, coloured according to the type of *CEBPA* mutation. For samples with multiple *CEBPA* mutations, we used the ordering as in **A** to decide which mutation to display. **C**) Kaplan-Meier curve of the survival of BEAT and TCGA patients in and outside the CEBPA^T cluster.

547

548 Figure 4: Gene expression profiling identifies five transcriptional *NPM1*-related clusters.

549 **A)** Waterfall plot of aberrations in the *NPM1*-related clusters, including the percentage of samples with 550 the aberration. The plot is combined with heatmaps showing the expression of marker genes and cell

551 type scores. The columns are samples, which are split according to transcriptional clusters. B) Boxplot 552 showing the scaled variant allele frequency (VAF) of mutated NPM1 from the BEAT, Leucegene, and 553 LUMC cohorts. The VAF was scaled per gene and study to allow for a combined analysis. We used a 554 two-sided Wilcoxon test to test for statistical differences and Benjamini-Hochberg to adjust p-values for 555 multiple testing. C) tSNE visualisation of patient samples, coloured according to the FAB annotation. Only 556 NPM1-related clusters are coloured; the rest are in grey. D) Fraction of FAB annotations per cluster. E) 557 and F) show boxplots of HLA I and HLA II antigen presenting cell scores, respectively. Tests were 558 performed as in **B**, but were only done between the two KMT2A^T, the five NPM1^T and the five AML-MRC^T 559 clusters. FDR values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001. HSC = hematopoietic stem cells, Prog. 560 = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. = monocytes, cDC 561 = conventional dendritic cells, VAF = variant allele frequency

562

563 Figure 5: Gene expression profiling identifies five transcriptional AML-MRC-related clusters

564 A) Waterfall plot of aberrations in the AML-MRC-related clusters, including the percentage of samples 565 with the aberration. We did not plot enriched individual large chromosomal mishaps. The plot is combined 566 with heatmaps showing the expression of marker genes and cell type scores. The columns are samples, 567 which are split according to transcriptional clusters. MRC genes are ASXL1, BCOR, EZH2, RUNX1, 568 SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2. Cytogenetic abnormalities are the ICC 2022 aberrations that 569 define AML-MRC with cytogenetic abnormalities. B) tSNE visualisation of patient samples, coloured 570 according to the FAB annotation. Only AML-MRC clusters samples are coloured are coloured; the rest 571 are in grey. C) Fraction of FAB annotations per cluster. D) Boxplots of cytolytic cell score per cluster. We 572 used a two-sided Wilcoxon test to test for statistical differences and Benjamini-Hochberg to adjust p-573 values for multiple testing. Tests were performed only between the two KMT2A^T, the five NPM1^T and the five AML-MRC^T clusters. FDR values: * < 0.05, ** < 0.01, *** < 0.005, **** < 0.001. HSC = hematopoietic 574 575 stem cells, Prog. = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. 576 = monocytes, cDC = conventional dendritic cells

577

578 Figure 6: AML clusters exhibit cell type-independent differences in ex-vivo drug responses

A) Heatmap coloured according to the median scaled area under the curve (AUC) of the ex-vivo drug
response per drug and cluster. On the left is the drug name, and on the right is the drug family. A green

581 colour indicates a lower median AUC for the drug for the samples in the cluster compared to the other 582 clusters, indicating a strong drug response. Red indicates a higher median AUC, meaning a weak drug 583 response. B) Boxplots showing ex-vivo drug responses for a selection of drugs. We performed 584 significance testing using a two-sided Wilcoxon test. FDR values: * < 0.05, ** < 0.01, *** < 0.05, **** < 585 0.001. C) Plots of the multivariate linear models with cluster membership and the six cell type scores as 586 independent variables and AUC as the dependent variable. On the x-axis, the coefficient of the variables 587 in the models is shown, and the y-axis shows the -log10 of the p-value for each variable. The shown p-588 values are not corrected and are for visualisation to indicate variable importance in the multivariate model. 589 The corrected p-values of the cluster membership variable are shown in Supplemental Table 3. The red 590 line indicates a p-value of 0.05. D) Barplots of the top 40 drugs with highest corrected p-values for Kruskal-591 Wallis tests between ex-vivo drug response and clusters or ICC 2022 diagnosis to test if there were

592 significant differences in the median AUCs. All p-values were corrected with Benjamini-Hochberg.



KMT2A fusions & NPM1 + trisomy 8/8q

Figure 2





- KMT2A::ELL
- KMT2A::MLLT1
- KMT2A::MLLT10
- O KMT2A::MLLT3
- KMT2A::MLLT4
- KMT2A::MLLT6
- KMT2A::SEPT6
- KMT2A::SEPT9
- O No KMT2A
- NPM1 + trisomy 8/8q
- Other KMT2A











